New depression drug SPT-300 moves to safety testing in extension trial
Symptom relief
ENROLLING_BY_INVITATION
This study is an extension of an earlier trial, testing the safety and tolerability of SPT-300 in 360 adults with major depressive disorder, with or without anxious distress. Participants who completed the prior study will receive SPT-300 for 6 weeks. The goal is to monitor side …
Phase: PHASE2 • Sponsor: Seaport Therapeutics • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC